LICENSE AND API SUPPLY AGREEMENTLicense and Api Supply Agreement • November 8th, 2013 • Cara Therapeutics, Inc. • Pharmaceutical preparations • Connecticut
THIS LICENSE AND API SUPPLY AGREEMENT (this “Agreement”) is made and entered into effective as of April 16th, 2012 (the “Effective Date”) by and between CHONG KUN DANG PHARMACEUTICALS CORP., a corporation organized under the laws of Korea with a principal place of business at 368, 3-ga, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Korea (“CKD”), and CARA THERAPEUTICS, INC., a Delaware corporation with a principal place of business at One Parrott Drive, Shelton, CT 06484 (“Cara”). Cara and CKD may be referred to herein individually as a “Party”, and collectively as the “Parties.”
CARA THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • November 8th, 2013 • Cara Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of the 25th day of April, 2013, by and between Cara Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any purchaser of Additional Shares (as defined in the Series D Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
LEASE By and between SHELTON PARROTT ASSOCIATES, L.L.C., as Landlord and CARA THERAPEUTICS, INC., as TenantLease • November 8th, 2013 • Cara Therapeutics, Inc. • Pharmaceutical preparations
Drafts presented under this Letter of Credit shall specify the number of this Letter of Credit as set forth above and shall be presented on or before the Expiration Date hereof. We hereby engage with you that drafts drawn under and in compliance with the terms of this Letter of Credit will be duly honored upon presentation to us.
AMENDMENT TO LICENSE AND API SUPPLY AGREEMENTLicense and Api Supply Agreement • November 8th, 2013 • Cara Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT TO LICENSE AND API SUPPLY AGREEMENT (the “Amendment”) is made and entered into effective as of May 1, 2012, by and between CHONG KUN DANG PHARMACEUTICALS CORP., a corporation organized under the laws of Korea with a principal place of business at 368, 3-ga, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Korea (“CKD”), and CARA THERAPEUTICS, INC., a Delaware corporation with a principal place of business at One Parrott Drive, Shelton, CT 06484 (“Cara”). Cara and CKD may be referred to herein individually as a “Party”, and collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • November 8th, 2013 • Cara Therapeutics, Inc. • Pharmaceutical preparations • Illinois
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of April 4, 2013 (the “Effective Date”) by and between MARUISHI PHARMACEUTICAL CO., LTD, having its place of business at 4-2, Imazu-Naka 2-Chome, Tsurumi-Ku, Osaka, 538-0042 Japan (“Maruishi”), and CARA THERAPEUTICS, INC., a Delaware corporation with a principal place of business at One Parrott Drive, Shelton, CT 06484 (“Cara”). Cara and Maruishi may be referred to herein individually as a “Party”, and collectively as the “Parties.”
